The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Grell, M., Douni, E., Wajant, H., Löhden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90192-2 · Cited by 1,325
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Transmembrane TNF- : structure, function and interaction with anti-TNF agents
Horiuchi, T., Mitoma, H., Harashima, S.-I., Tsukamoto, H., & Shimoda, T. (2010) · Rheumatology · doi:10.1093/rheumatology/keq031 · Cited by 864
Self-citationA Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling
Chan, F. K.-M., Chun, H. J., Zheng, L., Siegel, R. M., Bui, K. L., & Lenardo, M. J. (2000) · Science · doi:10.1126/science.288.5475.2351 · Cited by 856
Two tumour necrosis factor receptors: structure and function
Vandenabeele, P., Declercq, W., Beyaert, R., & Fiers, W. (1995) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)89088-1 · Cited by 799
TNF downmodulates the function of human CD4+CD25hi T-regulatory cells
Valencia, X., Stephens, G., Goldbach-Mansky, R., Wilson, M., Shevach, E. M., & Lipsky, P. E. (2006) · Blood · doi:10.1182/blood-2005-11-4567 · Cited by 781
Sedger, L. M., & McDermott, M. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 771
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Nie, H., Zheng, Y., Li, R., Guo, T. B., He, D., Fang, L., Liu, X., Xiao, L., Chen, X., Wan, B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3085 · Cited by 515
Nadkarni, S., Mauri, C., & Ehrenstein, M. R. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061531 · Cited by 507
Mahadevan, U., Wolf, D. C., Dubinsky, M., Cortot, A., Lee, S. D., Siegel, C. A., Ullman, T., Glover, S., Valentine, J. F., Rubin, D. T., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.11.011 · Cited by 498
Nesbitt, A., Fossati, G., Bergin, M., Stephens, P., Stephens, S., Foulkes, R., Brown, D., Robinson, M., & Bourne, T. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20225 · Cited by 477
A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact
Perez, C., Albert, I., DeFay, K., Zachariades, N., Gooding, L., & Kriegler, M. (1990) · Cell · doi:10.1016/0092-8674(90)90158-b · Cited by 403
TNF ligands and receptors – a matter of life and death
MacEwan, D. J. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704549 · Cited by 391
Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 368
Mitoma, H., Horiuchi, T., Tsukamoto, H., Tamimoto, Y., Kimoto, Y., Uchino, A., To, K., Harashima, S., Hatta, N., & Harada, M. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23447 · Cited by 346
Self-citationMechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Levin, A. D., Wildenberg, M. E., & van den Brink, G. R. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw053 · Cited by 336
Kaymakcalan, Z., Sakorafas, P., Bose, S., Scesney, S., Xiong, L., Hanzatian, D. K., Salfeld, J., & Sasso, E. H. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.002 · Cited by 317
Bruns, H., Meinken, C., Schauenberg, P., Härter, G., Kern, P., Modlin, R. L., Antoni, C., & Stenger, S. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38482 · Cited by 307
Eissner, G., Kolch, W., & Scheurich, P. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.011 · Cited by 298
Chen, X., Wu, X., Zhou, Q., Howard, O. M. Z., Netea, M. G., & Oppenheim, J. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202659 · Cited by 293
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
Wallis, R. S. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70227-5 · Cited by 275
Mitoma, H., Horiuchi, T., Hatta, N., Tsukamoto, H., Harashima, S.-I., Kikuchi, Y., Otsuka, J., Okamura, S., Fujita, S., & Harada, M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.060 · Cited by 270
Self-citationAtreya, R., Zimmer, M., Bartsch, B., Waldner, M. J., Atreya, I., Neumann, H., Hildner, K., Hoffman, A., Kiesslich, R., Rink, A. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.032 · Cited by 256
Shealy, D. J., Cai, A., Staquet, K., Baker, A., Lacy, E. R., Johns, L., Vafa, O., Gunn, G., Tam, S., Sague, S., et al. (2010) · mAbs · doi:10.4161/mabs.12304 · Cited by 243
Louis, E., El Ghoul, Z., Vermeire, S., Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J. ‐., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01871.x · Cited by 224
Vos, A. C. W., Wildenberg, M. E., Duijvestein, M., Verhaar, A. P., van den Brink, G. R., & Hommes, D. W. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.008 · Cited by 218
Friedmann, E., Hauben, E., Maylandt, K., Schleeger, S., Vreugde, S., Lichtenthaler, S. F., Kuhn, P.-H., Stauffer, D., Rovelli, G., & Martoglio, B. (2006) · Nature Cell Biology · doi:10.1038/ncb1440 · Cited by 201
Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro
Vos, A. C. W., Wildenberg, M. E., Arijs, I., Duijvestein, M., Verhaar, A. P., de Hertogh, G., Vermeire, S., Rutgeerts, P., van den Brink, G. R., & Hommes, D. W. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21818 · Cited by 200
Watts, A. D. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2119 · Cited by 195
Eissner, G., Kirchner, S., Lindner, H., Kolch, W., Janosch, P., Grell, M., Scheurich, P., Andreesen, R., & Holler, E. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6193 · Cited by 193
Nguyen, D. X., & Ehrenstein, M. R. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151255 · Cited by 184
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
Sandborn, W. J., Schreiber, S., Feagan, B. G., Rutgeerts, P., Younes, Z. H., Bloomfield, R., Coteur, G., Guzman, J. P., & D'Haens, G. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.04.031 · Cited by 175
Van den Brande, J. M. H., Koehler, T. C., Zelinkova, Z., Bennink, R. J., te Velde, A. A., ten Cate, F. J. W., van Deventer, S. J. H., Peppelenbosch, M. P., & Hommes, D. W. (2007) · Gut · doi:10.1136/gut.2006.105379 · Cited by 170
Grinberg-Bleyer, Y., Saadoun, D., Baeyens, A., Billiard, F., Goldstein, J. D., Grégoire, S., Martin, G. H., Elhage, R., Derian, N., Carpentier, W., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42945 · Cited by 167
Human pro-Tumor Necrosis Factor Is a Homotrimer
Tang, P., Hung, M.-C., & Klostergaard, J. (1996) · Biochemistry · doi:10.1021/bi952182t · Cited by 164
Wallis, R. S., & Ehlers, S. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.01.009 · Cited by 160
Nagar, M., Jacob‐Hirsch, J., Vernitsky, H., Berkun, Y., Ben‐Horin, S., Amariglio, N., Bank, I., Kloog, Y., Rechavi, G., & Goldstein, I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902070 · Cited by 156
Alexopoulou, L., Pasparakis, M., & Kollias, G. A. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271018 · Cited by 141
A γ-secretase-like intramembrane cleavage of TNFα by the GxGD aspartyl protease SPPL2b
Fluhrer, R., Grammer, G., Israel, L., Condron, M. M., Haffner, C., Friedmann, E., Böhland, C., Imhof, A., Martoglio, B., Teplow, D. B., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1450 · Cited by 140
Biancheri, P., Brezski, R. J., Sabatino, A. D., Greenplate, A. R., Soring, K. L., Corazza, G. R., Kok, K. B., Rovedatti, L., Vossenkämper, A., Ahmad, N., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.002 · Cited by 132
Kleijwegt, F. S., Laban, S., Duinkerken, G., Joosten, A. M., Zaldumbide, A., Nikolić, T., & Roep, B. O. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000560 · Cited by 132
Harashima, S., Horiuchi, T., Hatta, N., Morita, C., Higuchi, M., Sawabe, T., Tsukamoto, H., Tahira, T., Hayashi, K., Fujita, S., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.130 · Cited by 131
Self-citationPalframan, R. T., Airey, M., Moore, A., Vugler, A., & Nesbitt, A. M. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.009 · Cited by 120
Function and Regulation of Tumor Necrosis Factor Receptor Type 2
Carpentier, I., Coornaert, B., & Beyaert, R. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364694 · Cited by 117
McCann, F. E., Perocheau, D. P. B., Ruspi, G., Blazek, K. D., Davies, M. L., Feldmann, M., Dean, J. L. E., Stoop, A. A., & Williams, R. O. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38755 · Cited by 110
Boschetti, G., Nancey, S., Sardi, F., Roblin, X., Flourié, B., & Kaiserlian, D. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21308 · Cited by 107
Lymphotoxin and TNF: How it all began—A tribute to the travelers
Ruddle, N. H. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.02.001 · Cited by 102
Rossol, M., Meusch, U., Pierer, M., Kaltenhäuser, S., Häntzschel, H., Hauschildt, S., & Wagner, U. G. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4239 · Cited by 101
Chopra, M., Riedel, S. S., Biehl, M., Krieger, S., von Krosigk, V., Bäuerlein, C. A., Brede, C., Garrote, A.-L. J., Kraus, S., Schäfer, V., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt038 · Cited by 100
Suppressive activity of human regulatory T cells is maintained in the presence of TNF
Zaragoza, B., Chen, X., Oppenheim, J. J., Baeyens, A., Grégoire, S., Chader, D., Gorochov, G., Miyara, M., & Salomon, B. L. (2016) · Nature Medicine · doi:10.1038/nm.4019 · Cited by 97
Louis, E. J., Watier, H., Schreiber, S., Hampe, J., Taillard, F., Olson, A. D., Thorne, N., Zhang, H., & Colombel, J. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230421.12844.fd · Cited by 92
Kohno, T., Tam, L. T., Stevens, S. R., & Louie, J. S. (2007) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsymp.5650034 · Cited by 91
The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases
Blandizzi, C., Gionchetti, P., Armuzzi, A., Caporali, R. F., Chimenti, S., Cimaz, R., Cimino, L., Lapadula, G., Lionetti, P., Marchesoni, A., et al. (2014) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320140270s101 · Cited by 87
Toubi, E., Kessel, A., MAHMUDOV, Z., Halas, K., Rozenbaum, M., & Rosner, I. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.095 · Cited by 81
Moroi, R., Endo, K., Kinouchi, Y., Shiga, H., Kakuta, Y., Kuroha, M., Kanazawa, Y., Shimodaira, Y., Horiuchi, T., Takahashi, S., et al. (2013) · Immunogenetics · doi:10.1007/s00251-013-0679-8 · Cited by 79
Self-citationHarnessing Fc receptor biology in the design of therapeutic antibodies
Sondermann, P., & Szymkowski, D. E. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.005 · Cited by 76
Evidence that TNF-β (lymphotoxin α) can activate the inflammatory environment in human chondrocytes
Buhrmann, C., Shayan, P., Aggarwal, B. B., & Shakibaei, M. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4393 · Cited by 75
Caprioli, F., Bosè, F., Rossi, R. L., Petti, L., Viganò, C., Ciafardini, C., Raeli, L., Basilisco, G., Ferrero, S., Pagani, M., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318280292b · Cited by 72
Lazdins, J. K., Grell, M., Walker, M. R., Woods-Cook, K., Scheurich, P., & Pfizenmaier, K. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.1.81 · Cited by 71
Higuchi, M., Nagasawa, K., Horiuchi, T., Oike, M., Ito, Y., Yasukawa, M., & Niho, Y. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1996.4291 · Cited by 70
Self-citationRutgeerts, P., Sandborn, W. J., Fedorak, R. N., Rachmilewitz, D., Tarabar, D. K., Gibson, P. G., Nielsen, O. H., Wild, G., Schreiber, S., Rossi, C. P., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.022 · Cited by 67
Peck, R., Brockhaus, M., & Frey, J. R. (1989) · Cellular Immunology · doi:10.1016/0008-8749(89)90143-3 · Cited by 67
Ueda, N., Tsukamoto, H., Mitoma, H., Ayano, M., Tanaka, A., Ohta, S.-I., Inoue, Y., Arinobu, Y., Niiro, H., Akashi, K., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318280b169 · Cited by 65
Self-citationTernant, D., Berkane, Z., Picon, L., Gouilleux‐Gruart, V., Colombel, J., Allez, M., Louis, E. J., & Paintaud, G. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0225-3 · Cited by 65
Molecular aspects of human FcγR interactions with IgG: Functional and therapeutic consequences
Sibéril, S., Dutertre, C., Boix, C., Bonnin, E., Ménez, R., Stura, E. A., Jorieux, S., Fridman, W. H., & Teillaud, J. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.05.009 · Cited by 59
Identification of a major binding site for complement C3 on the IgG1 heavy chain.
Shohet, J. M., Pemberton, P. A., & Carroll, M. C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53400-1 · Cited by 57
Sahu, A., & Pangburn, M. K. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)62004-1 · Cited by 54
Kennedy, W. P., Campos, J. A. S., Offutt, C., Horn, P., Herman, A. E., Townsend, M. J., Tang, M. T., Grogan, J. L., Hsieh, F., & Davis, J. C. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0467-3 · Cited by 53
Fc Gamma Receptor CD64 Modulates the Inhibitory Activity of Infliximab
Wojtal, K. A., Rogler, G., Scharl, M. M., Biedermann, L., Frei, P., Fried, M., Weber, A., Eloranta, J. J., Kullak-Ublick, G. A., & Vavricka, S. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043361 · Cited by 50
Birkland, T. P., Sypek, J. P., & Wyler, D. J. (1992) · Journal of Leukocyte Biology · doi:10.1002/jlb.51.3.296 · Cited by 48
Receptor-like properties of the 26 kDa transmembrane form of TNF.
Domonkos, Á., Udvardy, A., László, L., Nagy, T., & Duda, E. (2001) · PubMed · Cited by 46
Influence of reverse signaling via membrane TNF-α on cytotoxicity of NK92 cells
Yu, M., Shi, W., Zhang, J., Niu, L., Chen, Q., Yan, D., Liu, T., Jing, W., Jiang, X., Wei, F., et al. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.09.001 · Cited by 42
Bedini, C., Nasorri, F., Girolomoni, G., Pità, O. D., & Cavani, A. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07945.x · Cited by 41
Xin, L., Wang, J., Zhang, H., et al. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.18.5.885 · Cited by 40
Kresse, M., Latta, M. R., Künstle, G., Riehle, H., van Rooijen, N., Hentze, H., Tiegs, G., Biburger, M., Lucas, R., & Wendel, A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.4076 · Cited by 40
The covalent interaction of C3 with IgG immune complexes
Vivanco, F., Muñoz, E., Vidarte, L., & Pastor‐Vargas, C. (1999) · Molecular Immunology · doi:10.1016/s0161-5890(99)00105-4 · Cited by 32
Armstrong, L., THICKETT, D. R., Christie, S. J., Kendall, H., & Millar, A. (2000) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.22.1.3728 · Cited by 31
Derer, S., Till, A., Häsler, R., Sina, C., Grabe, N., Jung, S., Nikolaus, S., Kuehbacher, T., Groetzinger, J., Rose‐John, S., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300384 · Cited by 30
Serine 132 Is the C3 Covalent Attachment Point on the CH1 Domain of Human IgG1
Vidarte, L., Pastor‐Vargas, C., Mas, S., Blázquez, A.-B., Ríos, V. D. L., Guerrero, R., & Vivanco, F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104870200 · Cited by 29
Localization of the human complement component C3 binding site on the IgG heavy chain.
Shohet, J. M., Bergamaschini, L. C., Davis, A. E., et al. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55092-4 · Cited by 28
Neregård, P., Krishnamurthy, A., Revu, S. K., Engström, M., af Klint, E., & Catrina, A. (2013) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2013.834964 · Cited by 25
Fishman, M. (1991) · Cellular Immunology · doi:10.1016/0008-8749(91)90066-k · Cited by 17
Expression of soluble and functional human neonatal Fc receptor in Pichia pastoris
Lee, C., Choi, D.-K., Choi, H., Song, M.-Y., & Kim, Y. (2009) · Protein Expression and Purification · doi:10.1016/j.pep.2009.12.004 · Cited by 17
Cited by
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications
Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., & Qiu, Q. (2022) · Cells · doi:10.3390/cells11213362 · Cited by 300
Anti-TNF Therapy in Crohn’s Disease
Adegbola, S. O., Sahnan, K., Warusavitarne, J., Hart, A., & Tozer, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082244 · Cited by 274
Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies
Mueller, A.-L., Payandeh, Z., Mohammadkhani, N., Mubarak, S. M. H., Zakeri, A., Alagheband Bahrami, A., Brockmueller, A., & Shakibaei, M. (2021) · Cells · doi:10.3390/cells10113017 · Cited by 256
RNA editing: Expanding the potential of RNA therapeutics
Booth, B. J., Nourreddine, S., Katrekar, D., Savva, Y., Bose, D., Long, T. J., Huss, D. J., & Mali, P. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.005 · Cited by 171
Lysosomal amino acid transporters as key players in inflammatory diseases
Toyama-Sorimachi, N., & Kobayashi, T. (2021) · International Immunology · doi:10.1093/intimm/dxab069 · Cited by 14
Metadata
- Authors
- Mitoma, H., Horiuchi, T., Tsukamoto, H., & Ueda, N.
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 101
- Pages
- 56-63
- ISSN
- 1043-4666 (ISSN-L)
- OpenAlex
- W2510966451
- Cited by
- 316
- References
- 90
- FWCI
- 16.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.